Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation
Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engstrom BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernas H, Skrtic S
Published in Journal of Clinical Endocrinology & Metabolism
Methodology
Randomised, open-label crossover trial comparing once-daily dual-release hydrocortisone with thrice-daily conventional hydrocortisone in adrenal insufficiency.
Key Findings
Dual-release hydrocortisone produced a more physiological cortisol profile with reduced body weight, blood pressure and HbA1c compared with conventional dosing.
Conclusions
Optimising glucocorticoid replacement pharmacokinetics improves cardiometabolic outcomes in adrenal insufficiency.
Limitations
Open-label design; modest sample; surrogate cardiometabolic endpoints.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.